A phase 1b/2 trial of the PLK1 inhibitor onvansertib in combination with FOLFIRI-bev in 2L treatment of KRAS-mutated (mKRAS) metastatic colorectal carcinoma (mCRC)

被引：5
|
作者：
Lenz, Heinz-Josef
Kasi, Anup
Mendelsohn, Lawrence
Cannon, Timothy Lewis
Starr, Jason S.
Hubbard, Joleen M.
Bekaii-Saab, Tanios S.
Ridinger, Maya
Samuelsz, Errin
Ruffner, Katherine L.
Erlander, Mark G.
Ahn, Daniel H.
机构：
[1] Univ Southern Calif, Keck Sch Med, Los Angeles, CA 90007 USA
[2] Univ Kansas, Ctr Canc, Westwood, KS USA
[3] Little Rock Hem Onc Assoc, Little Rock, AR USA
[4] Inova Schar Canc Inst, Fairfax, VA USA
[5] Univ Florida, Hlth Canc Ctr, Jacksonville, FL USA
[6] Mayo Clin, Rochester, MN USA
[7] Mayo Clin, Div Hematol Oncol, Phoenix, AZ USA
[8] Cardiff Oncol, San Diego, CA USA
[9] Mayo Clin, Phoenix, AZ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 04期
关键词：
D O I：
10.1200/JCO.2022.40.4_suppl.100
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
100
引用
收藏
页数：3
相关论文
共 50 条
  • [41] A Novel Combination Treatment Targeting BCL-XL and MCL1 for KRAS/BRAF-mutated and BCL2L1-amplified Colorectal Cancers
    Cho, Sung-Yup
    Han, Jee Yun
    Na, Deukchae
    Kang, Wonyoung
    Lee, Ahra
    Kim, Jooyoung
    Lee, Jieun
    Min, Seoyeon
    Kang, Jinjoo
    Chae, Jeesoo
    Kim, Jong-Il
    Park, Hansoo
    Lee, Won-Suk
    Lee, Charles
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (10) : 2178 - 2190
  • [42] BXQ-350: A phase 1b/2 placebo controlled, double blinded study on the efficacy and safety of BXQ-350 in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal carcinoma (mCRC)
    Patel, Reema Anil
    Baron, Ari David
    Boulmay, Brian C.
    Flora, Daniel Blake
    Gemmill, Julie Anne L.
    Lee, Fa Chyi
    Sohal, Davendra
    Williams, Grant Richard
    Curry, Richard Charles
    Gazda, Michael
    Purvis, Joseph D.
    Tapolsky, Gilles
    Takigiku, Ray
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : TPS224 - TPS224
  • [43] Phase 1b/2 trial of pepinemab plus avelumab as second line combination immunotherapy for patients with metastatic pancreatic adenocarcinoma.
    Ruffolo, Luis I.
    Fisher, Terrence Lee
    Evans, Elizabeth E.
    Mallow, Crystal L.
    Boise, Megan
    Foster, Amber
    Leonard, John E.
    Belt, Brian A.
    Yeh, Jen Jen
    Zauderer, Maurice
    Linehan, David
    Mulkerin, Daniel
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [44] A PHASE 2 TRIAL OF SALVAGE TREATMENT WITH GEMCITABINE AND S-1 COMBINATION IN HEAVILY PRETREATED PATIENTS WITH METASTATIC COLORECTAL CANCER
    Sym, S. J.
    Hong, J.
    Ahn, H. K.
    Park, J.
    Cho, E. K.
    Lee, J. H.
    Lee, W.
    Baek, J.
    Park, Y. H.
    Shin, D. B.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S3 - S3
  • [45] First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b-2 trial
    Thibaudin, Marion
    Fumet, Jean-David
    Limagne, Emeric
    Hampe, Lea
    Daumoine, Susy
    Derangere, Valentin
    Laheurte, Caroline
    Adotevi, Olivier
    Truntzer, Caroline
    Ghiringhelli, Francois
    CANCER RESEARCH, 2024, 84 (07)
  • [46] A Phase 1b/2 Study of the BET inhibitor ZEN003694 in combination with talazoparib for treatment of patients with TNBC without gBRCA1/2 mutations
    Aftimos, Philippe
    Oliveira, Mafalda
    Punie, Kevin
    Boni, Valentina
    Hamilton, Erika
    Gucalp, Ayca
    Shah, Payal
    Mina, Lida
    Sharma, Priyanka
    Bauman, Lisa
    Campeau, Eric
    Attwell, Sarah
    Snyder, Margo
    Norek, Karen
    Czibere, Akos
    Yu, Yanke
    Silverman, Michael H.
    Lakhotia, Sanjay
    Domchek, Susan
    Litton, Jennifer
    Robson, Mark
    CANCER RESEARCH, 2021, 81 (04)
  • [47] Sotorasib (soto), panitumumab (pani) and FOLFIRI in the first-line (1L) setting for KRAS G12C-mutated metastatic colorectal cancer (mCRC): Safety and efficacy analysis from the phase Ib CodeBreaK 101 study
    Siena, S.
    Yamaguchi, K.
    Ruffinelli Rodriguez, J. C.
    Corral de la Fuente, E.
    Kuboki, Y.
    Cremolini, C.
    Victoria Ruiz, I.
    Elez Fernandez, M. E.
    Strickler, J. H.
    Furqan, M.
    Bashir, B.
    Nduka, C.
    Hippenmeyer, J.
    Chan, E.
    Xia, C.
    Masuishi, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S429 - S430
  • [48] Phase 1b/2a clinical trial of the oral BET inhibitor PLX2853 as monotherapy for ARID1A mutated gynecologic cancers and in combination with carboplatin for platinum resistant ovarian cance
    Swisher, Elizabeth M.
    Duska, Linda R.
    Hamilton, Erika P.
    Oza, Amit M.
    Fleming, Gini
    Yeku, Oladapo O.
    Spira, Alexander I.
    Richardson, Debra L.
    Guo, Robin
    Walling, Jackie
    Inokuchi, Kerry
    Zamarin, Dmitriy
    CANCER RESEARCH, 2023, 83 (08)
  • [49] A phase 1b/2 study combining MM-151+nal-IRI+5-FU + leucovorin in RAS-wildtype metastatic colorectal cancer (mCRC)
    Chan, Emily
    Harb, Wael A.
    Mody, Kabir
    Jiang, Xiaoy
    McClure, Ty
    Kearns, Jeffrey D.
    Valencia, Andrea
    Fitzgerald, Jonathan
    Pipas, J. Marc
    Nering, Rachel
    Lewis, Lionel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [50] BXQ-350, a novel sphingolipid metabolism modulator, in combination with mFOLFOX7 and bevacizumab in newly diagnosed metastatic colorectal cancer (mCRC) patients: A phase 1b/2 randomized study.
    Flora, Daniel Blake
    Patel, Reema Anil
    Lee, Fa-Chyi
    Tapolsky, Gilles
    Takigiku, Ray
    Beach, Jim
    Gazda, Michael
    Arshad, Tariq
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : TPS320 - TPS320
12345